Grafting of functional motifs onto protein scaffolds identified by PDB screening - An efficient route to design optimizable protein binders

FEBS Journal

Volumn 280, Issue 1, 2013, Pages 139-159

  Tlatli, Rym ^a   Nozach, Hervé ^a   Collet, Guillaume ^a   Beau, Fabrice ^a   Vera, Laura ^a   Stura, Enrico ^a   Dive, Vincent ^a   Cuniasse, Philippe ^a  

^a Institute Frederic Joliot   (France)

Author keywords

functional motif; grafting; MMP inhibitor; protein binder design; protein protein interactions

Indexed keywords

GELATINASE A; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE 14; NEUTROPHIL COLLAGENASE; SCAFFOLD PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; BINDING AFFINITY; BINDING SITE; CATALYSIS; COMPLEX FORMATION; COMPUTER MODEL; CONTROLLED STUDY; CRYSTAL STRUCTURE; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN BINDING; PROTEIN DATA BANK; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN SYNTHESIS; RESIDUE ANALYSIS; SCREENING TEST; STATIC ELECTRICITY;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DATABASES, PROTEIN; HUMANS; HYDROGEN BONDING; MATRIX METALLOPROTEINASE 12; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITORS; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN STABILITY; RECOMBINANT FUSION PROTEINS; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84872021687     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12056     Document Type: Article

References (66)

1. Gebauer M, &, Skerra A, (2009) Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Cheml Biol 13, 245-255.
2. Beck A, Wurch T, Bailly C, &, Corvaia N, (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10, 345-352.
3. DeLano WL, Ultsch MH, de Vos AM, &, Wells JA, (2000) Convergent solutions to binding at a protein-protein interface. Science 287, 1279-1283.
4. Vita C, Drakopoulou E, Vizzavona J, Rochette S, Martin L, Menez A, Roumestand C, Yang YS, Ylisastigui L, Benjouad A, et al,. (1999) Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. Proc Natl Acad Sci USA 96, 13091-13096.
5. Domingues H, Cregut D, Sebald W, Oschkinat H, &, Serrano L, (1999) Rational design of a GCN4-derived mimetic of interleukin-4. Nat Struct Biol 6, 652-656.
6. Martin L, Stricher F, Misse D, Sironi F, Pugniere M, Barthe P, Prado-Gotor R, Freulon I, Magne X, Roumestand C, et al,. (2003) Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat Biotechnol 21, 71-76.
7. Sia SK, &, Kim PS, (2003) Protein grafting of an HIV-1-inhibiting epitope. Proc Natl Acad Sci USA 100, 9756-9761.
8. Cobos ES, Pisabarro MT, Vega MC, Lacroix E, Serrano L, Ruiz-Sanz J, &, Martinez JC, (2004) A miniprotein scaffold used to assemble the polyproline II binding epitope recognized by SH3 domains. J Mol Biol 342, 355-365.
9. Li C, Liu M, Monbo J, Zou GZ, Li CQ, Yuan WR, Zella D, Lu WY, &, Lu WY, (2008) Turning a scorpion toxin into an antitumor miniprotein. J Am Chem Soc 130, 13546-13548.
10. Azoitei ML, Correia BE, Ban YEA, Carrico C, Kalyuzhniy O, Chen L, Schroeter A, Huang PS, McLellan JS, Kwong PD, et al,. (2011) Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science 334, 373-376.
11. Azoitei ML, Ban YEA, Julien JP, Bryson S, Schroeter A, Kalyuzhniy O, Porter JR, Adachi Y, Baker D, Pai EF, et al,. (2012) Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope. J Mol Biol 415, 175-192.
12. Liang SD, Li WZ, Xiao L, Wang JS, &, Lai LH, (2000) Grafting of protein-protein interaction epitope. J Biomol Struct Dynamics 17, 821-828.
13. Magis C, Gasparini D, Lecoq A, Le Du MH, Stura E, Charbonnier JB, Mourier G, Boulain JC, Pardo L, Caruana A, et al,. (2006) Structure-based secondary structure-independent approach to design protein ligands: application to the design of Kv1.2 potassium channel blockers. J Am Chem Soc 128, 16190-16205.
14. Keskin O, &, Nussinov R, (2005) Favorable scaffolds: proteins with different sequence, structure and function may associate in similar ways. Protein Eng Des Sel 18, 11-24.
15. Keskin O, &, Nussinov R, (2007) Similar binding sites and different partners: implications to shared proteins in cellular pathways. Structure 15, 341-354.
16. Debret G, Martel A, &, Cuniasse P, (2009) Rasmot-3d Pro: a 3D motif search webserver. Nucleic Acids Res 37, W459-W464.
17. Zhang CS, &, Lai LH, (2012) AutoMatch: target-binding protein design and enzyme design by automatic pinpointing potential active sites in available protein scaffolds. Proteins 80, 1078-1094.
18. Liu S, Liu S, Zhu X, Liang H, Cao A, Chang Z, &, Lai L, (2007) Nonnatural protein-protein interaction-pair design by key residues grafting. Proc Natl Acad Sci USA 104, 5330-5335.
19. Fleishman SJ, Whitehead TA, Ekiert DC, Dreyfus C, Corn JE, Strauch EM, Wilson IA, &, Baker D, (2011) Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science 332, 816-821.
20. McCawley LJ, &, Matrisian LM, (2001) Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 13, 534-540.
21. Rydlova M, Holubec L, Ludvikova M, Kalfert D, Franekova J, Povysil C, &, Ludvikova M, (2008) Biological activity and clinical implications of the matrix metalloproteinases. Anticancer Res 28, 1389-1397.
22. Whittaker M, Floyd CD, Brown P, &, Gearing AJH, (1999) Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 99, 2735-2776.
23. Cuniasse P, Devel L, Makaritis A, Beau F, Georgiadis D, Matziari A, Yiotakis A, &, Dive V, (2005) Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs. Biochimie 87, 393-402.
24. Fisher JF, &, Mobashery S, (2006) Recent advances in MMP inhibitor design. Cancer Metast Rev 25, 115-136.
25. Tu GG, Xu WF, Huang HM, &, Li SH, (2008) Progress in the development of matrix metalloproteinase inhibitors. Curr Med Chem 15, 1388-1395.
26. Yiotakis A, &, Dive V, (2008) Synthetic active site-directed inhibitors of metzincins: achievement and perspectives. Mol Aspects Med 29, 329-338.
27. Bode W, (2003) Structural basis of matrix metalloproteinase function. Biochem Soc Symp 70, 1-14.
28. Tallant C, Marrero A, &, Gomis-Ruth FX, (2010) Matrix metalloproteinases: fold and function of their catalytic domains. Biochim Biophys Acta 1803, 20-28.
29. Brew K, Dinakarpandian D, &, Nagase H, (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477, 267-283.
30. Butler GS, Hutton M, Wattam BA, Williamson RA, Knauper V, Willenbrock F, &, Murphy G, (1999) The specificity of TIMP-2 for matrix metalloproteinases can be modified by single amino acid mutations. J Biol Chem 274, 20391-20396.
31. Meng Q, Malinovskii V, Huang W, Hu YJ, Chung L, Nagase H, Bode W, Maskos K, &, Brew K, (1999) Residue 2 of TIMP-1 is a major determinant of affinity and specificity for matrix metalloproteinases but effects of substitutions do not correlate with those of the corresponding P1' residue of substrate. J Biol Chem 274, 10184-10189.
32. Wei S, Chen Y, Chung L, Nagase H, &, Brew K, (2003) Protein engineering of the tissue inhibitor of metalloproteinase 1 (TIMP-1) inhibitory domain-in search of selective matrix metalloproteinase inhibitors. J Biol Chem 278, 9831-9834.
33. Hamze AB, Wei S, Bahudhanapati H, Kota S, Acharya KR, &, Brew K, (2007) Constraining specificity in the N-domain of tissue inhibitor of metalloproteinases-1; gelatinase-selective inhibitors. Protein Sci 16, 1905-1913.
34. GomisRuth FX, Maskos K, Betz M, Bergner A, Huber R, Suzuki K, Yoshida N, Nagase H, Brew K, Bourenkov GP, et al,. (1997) Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 389, 77-81.
35. Fernandez-Catalan C, Bode W, Huber R, Turk D, Calvete JJ, Lichte A, Tschesche H, &, Maskos K, (1998) Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor. EMBO J 17, 5238-5248.
36. Morgunova E, Tuuttila A, Bergmann U, &, Tryggvason K, (2002) Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2. Proc Natl Acad Sci USA 99, 7414-7419.
37. Maskos K, Lang R, Tschesche H, &, Bode W, (2007) Flexibility and variability of TIMP binding: X-ray structure of the complex between collagenase-3/MMP-13 and TIMP-2. J Mol Biol 366, 1222-1231.
38. Higashi S, &, Miyazaki K, (1999) Reactive site-modified tissue inhibitor of metalloproteinases-2 inhibits the cell-mediated activation of progelatinase A. J Biol Chem 274, 10497-10504.
39. Troeberg L, Tanaka M, Wait R, Shi YE, Brew K, &, Nagase H, (2002) E. coli expression of TIMP-4 and comparative kinetic studies with TIMP-1 and TIMP-2: insights into the interactions of TIMPs and matrix metalloproteinase 2 (gelatinase A). Biochemistry 41, 15025-15035.
40. Blomberg N, Gabdoulline RR, Nilges M, &, Wade RC, (1999) Classification of protein sequences by homology modeling and quantitative analysis of electrostatic similarity. Proteins 37, 379-387.
41. Baker NA, Sept D, Joseph S, Holst MJ, &, McCammon JA, (2001) Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci USA 98, 10037-10041.
42. Lo Conte L, Chothia C, &, Janin J, (1999) The atomic structure of protein-protein recognition sites. J Mol Biol 285, 2177-2198.
43. Jones S, &, Thornton JM, (1996) Principles of protein-protein interactions. Proc Natl Acad Sci USA 93, 13-20.
44. Xu D, Tsai CJ, &, Nussinov R, (1997) Hydrogen bonds and salt bridges across protein-protein interfaces. Protein Eng 10, 999-1012.
45. Guerois R, Nielsen JE, &, Serrano L, (2002) Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J Mol Biol 320, 369-387.
46. Peisajovich SG, &, Tawfik DS, (2007) Protein engineers turned evolutionists. Nat Methods 4, 991-994.
47. Lauer-Fields JL, Cudic M, Wei S, Mari F, Fields GB, &, Brew K, (2007) Engineered sarafotoxins as tissue inhibitor of metalloproteinases-like matrix metalloproteinase inhibitors. J Biol Chem 282, 26948-26955.
48. Huang CC, Stricher F, Martin L, Decker JM, Majeed S, Barthe P, Hendrickson WA, Robinson J, Roumestand C, Sodroski J, et al,. (2005) Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120: crystal structures, molecular mimicry, and neutralization breadth. Structure 13, 755-768.
49. Bahudhanapati H, Zhang YN, Sidhu SS, &, Brew K, (2011) Phage display of tissue inhibitor of metalloproteinases-2 (TIMP-2): identification of selective inhibitors of collagenase-1 (metalloproteinase 1 (MMP-1)). J Biol Chem 286, 31761-31770.
50. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, &, Karplus M, (1983) CHARMM-a program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 4, 187-217.
51. MacKerell AD, Bashford D, Bellott M, Dunbrack RL, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, et al,. (1998) All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 102, 3586-3616.
52. Sitkoff D, Sharp KA, &, Honig B, (1994) Accurate calculation of hydration free-energies using macroscopic solvent models. J Phys Chem 98, 1978-1988.
53. Madura JD, Briggs JM, Wade RC, Davis ME, Luty BA, Ilin A, Antosiewicz J, Gilson MK, Bagheri B, Scott LR, et al,. (1995) Electrostatics and diffusion of molecules in solution-simulations with the University of Houston Brownian dynamics program. Comput Phys Commun 91, 57-95.
54. Wade RC, Gabdoulline RR, &, De Rienzo F, (2001) Protein interaction property similarity analysis. Int J Quantum Chem 83, 122-127.
55. Hodgkin EE, &, Richards WG, (1987) Molecular similarity based on electrostatic potential and electric field. Int J Quantum Chem 32, 105-110.
56. Campos ITN, Amino R, Sampaio CAM, Auerswald EA, Friedrich T, Lemaire HG, Schenkman S, &, Tanaka AS, (2002) Infestin, a thrombin inhibitor presents in Triatoma infestans midgut, a Chagas' disease vector: gene cloning, expression and characterization of the inhibitor. Insect Biochem Mol 32, 991-997.
57. Stubbs MT, Morenweiser R, Sturzebecher J, Bauer M, Bode W, Huber R, Piechottka GP, Matschiner G, Sommerhoff CP, Fritz H, et al,. (1997) The three-dimensional structure of recombinant leech-derived tryptase inhibitor in complex with trypsin-implications for the structure of human mast cell tryptase and its inhibition. J Biol Chem 272, 19931-19937.
58. Valdez-Cruz NA, Conde R, Zamudio F, &, Possani LD, (2011) Anticoagulants from scorpion venoms. In Toxins and Homeostasis: From Bench to Bedside (, Marklan FS, ed.), pp. 255-266, Springer, NY, USA.
59. Sommerhoff CP, Avrutina O, Schmoldt HU, Gabrijelcic-Geiger D, Diederichsen U, &, Kolmar H, (2010) Engineered cystine knot miniproteins as potent inhibitors of human mast cell tryptase β. J Mol Biol 395, 167-175.
60. Devel L, Rogakos V, David A, Makaritis A, Beau F, Cuniasse P, Yiotakis A, &, Dive V, (2006) Development of selective inhibitors and substrate of matrix metalloproteinase-12. J Biol Chem 281, 11152-11160.
61. Horovitz A, &, Levitzki A, (1987) An accurate method for determination of receptor ligand and enzyme-inhibitor dissociation constants from displacement curves. Proc Natl Acad Sci USA 84, 6654-6658.
62. Leslie AGW, (2006) The integration of macromolecular diffraction data. Acta Crystallogr D 62, 48-57.
63. Murshudov GN, Vagin AA, &, Dodson EJ, (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D 53, 240-255.
64. Devel L, Garcia S, Czarny B, Beau F, Lajeunesse E, Vera L, Georgiadis D, Stura E, &, Dive V, (2010) Insights from selective non-phosphinic inhibitors of MMP-12 tailored to fit with an S-1' loop canonical conformation. J Biol Chem 285, 35900-35909.
65. Bailey S, (1994) The Ccp4 suite-programs for protein crystallography. Acta Crystallogr D 50, 760-763.
66. Emsley P, Lohkamp B, Scott WG, &, Cowtan K, (2010) Features and development of Coot. Acta Crystallogr D 66, 486-501.